Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.
Alison M SchramIgor OdintsovMadelyn Espinosa-CottonInna KhodosWhitney J SissoMarissa S MattarAllan J W LuiMorana VojnicSara H ShameemThrusha ChauhanJean TorrisiJim FordMarie N O'ConnorCecile A W GeuijenRon C J SchackmannJeroen J Lammerts van BuerenErnesto WassermanElisa De StanchinaEileen M O'ReillyMarc LadanyiAlexander E DrilonRomel SomwarPublished in: Cancer discovery (2022)
NRG1 rearrangements encode chimeric ligands that activate the ERBB receptor tyrosine kinase family. Here we show that targeting HER2 and HER3 simultaneously with the bispecific antibody Zeno leads to durable clinical responses in patients with NRG1 fusion-positive cancers and is thus an effective therapeutic strategy. This article is highlighted in the In This Issue feature, p. 1171.